Camtek vs Orbotech, the Latest Developments

May 7, 2013

tweedle dee and tweedle dum

In the ongoing patent saga between Camtek and Orbotech, two Israeli manufacturers of optical imaging systems for quality control of semiconductor substrates, Camtek, represented by Adv. Adi Levit, petitioned to correct the statement of case concerning their opposition to Orbotech’s patent no. 179995 titled “SYSTEM AND METHOD FOR INSPECTING PATTERNED DEVICES HAVING MICROSCOPIC CONDUCTORS”

Evidence has already been presented, but some of Camtek’s evidence was struck as irrelevant. This attempt to correct the statement of case was, according to Orbotech, represented by Adv. Reuven Borchowsky, an attempt to bring into discussion material that has already been ruled as irrelevant and subsequently appealed and upheld.

The case was allowed on the 30 October 2011 and the appeal was filed (as is customary to delay allowance for as long as possible), on 31 January 2012. the attempt to correct the statement of case was filed on 19 March 2013, only just over a month before a hearing due for 22 April  2013

Adv. Levit argued that the correction was required because of the public interest of maintaining the ‘purity of the register’. In other words, if Orbtech don’t deserve a patent for lack of novelty, inventive step, and / or utility, civil procedure should be waived in the interest of making sure that they don’t get one.   The issue seems to be about the angle of the azimuth being claimed but not properly supported. Orbotech disagreed with a change in direction late in the proceedings.

The arbitrator (not signed so not sure who), seems to be accusing Camtek of time-wasting shenanigans, and rejected the request, ruling that the purity of the register was not a be all and end all blanket legitimacy for everything, and hinting at inequitable behavior. She also ruled NIS 3000 of costs to the applicant.

COMMENTS

We suspect that both parties are motivated by a mixture of commercial interests and bad feelings, and the purity or otherwise of the register is not a significant consideration here. It is legitimate for the opposer’s counsel to file responses on the last day, as it is his client’s interest to stop the patent issuing for as long as possible. Additional delays, especially when not based on newly discovered evidence, is intolerable.  the ruling is a reasonable one, if a little formalistic and dry.  To be honest, I’ve lost interest in the little skirmishes and await a final ruling on the validity of the patent. On the other hand, a heavy case load could be responsible for not filing request to amend the statement of case a little earlier. We note that most Paris Convention filings seem to wait until the last day. It is not inequitable behavior, just procrastination.


Genentech Withdraws Israel Patent

May 6, 2013

genentech

Genentech filed and received allowance of Israel Patent Number 175885 titled “ANTIBODY, A FRAGMENT THEREOF, A METHOD OF PREPARING THE SAME AND A USE OF THE ANTIBODY”. the patent issued on 29 May 2011 and was next due to be renewed on 17 December 2014.

On  24 April 2013, Genentech requested to withdraw the patent. Actually, the claim this was their second attempt to withdraw the patent, having first asked to do so on 21 March 2013.

Patentees are able to request that a valid patent be withdrawn, and the effect of so doing is as if the patent had never issued. The request has published for opposition purposes.

COMMENT

I wonder what is going on here?


Opposition Withdrawn and Patent Allowed

May 6, 2013

stencil

In Febrary 2007, Israel patent Number 171865 to Speedline technologies, titled METHOD AND APPARATUS FOR SIMULTANEOUS INSPECTION AND CLEANING OF A STENCIL published for opposition purposes, and an opposition was filed in may 2007.  It has now, six years later been  withdrawn. In a brief statement, Ms Yaara Shoshani Caspi has ruled that she does not see any reason to continue the opposition as an in partes procedure with the patent office taking an inquisitional position. The application will therefore be allowed.

COMMENTS

This announcement tells nothing of the reasons for opposition or why Ms Shoshani caspi ruled that there was no public interest justification to prevent the application for issuing. This information is also not on the IPO website. If someone reviews the file and submits a request for cancellation, no doubt we will be wiser.


Reviving Lapsed Israel Patents – Human Error Preferable to Financial Problems

May 5, 2013

meter lapsed

Eli Tiar allowed his patent number 148847 titled “EARTH SCREW ANCHOR ASSEMBLY” to go abandoned. The patent was filed in March 2002, and granted in February 2011. The first and second renewals, for years 1-6 and 7-10 were timely paid, but the third renewal, due March 2012, was not paid, due to lack of funds and commercial interest.

The Deputy Commissioner, Ms Jaqueline Bracha, did not consider this excuse as a legitimate reason to allow the abandoned patent to publish for reinstatement, since the law requires the patentee to take immediate steps on becoming aware that the patent lapsed. In this case, the patentee was aware that the patent would and then had lapsed, but made a financial decision to allow this to happen. This cannot be considered unintentional. The request to revive was therefore rejected.

On the other hand, Israel Patent 151594 to Biomar Israel LTD. for a FUNGICIDE COMPOSITION CONTAINING TEA TREE OIL was supposed to be renewed on 4 September 2012, and lapsed six months later on 4 May 2013, after the grace period passed. However, as evidenced by an affidavit, the agent responsible for maintenance was changed, from Dr Eyal Bressler to Daniel Faigelson, and a human error was made in entering the renewal data.  The applicant never intended the application to lapse, and so Ms Jaqueline Bracha ordered that its reinstatement was allowed to publish for opposition purposes.

Israel patent number 161941 titled SHELF-STABLE VEGETABLE COMPOSITION AND METHOD OF MAKING to the Societe des Produits Nestle SA lapsed since the patentee misinformed a renewal service, informing them that the next renewal was due in 2012, but in fact it was due in 2008. The mistake was spotted in 2013,  and the company took immediate action to rectify the situation. Ms Jaqueline Bracha ordered that its reinstatement was allowed to publish for opposition purposes. She also has set up an inquiry to determine why a notice of the patent becoming abandoned wasn’t sent out earlier, although notes that this service is not obligatory on the patent office, and cannot, itself be blamed for patents lapsing.

Israel Patent Number 158611 to IBM titledMETHOD FOR INTEROPERATION BETWEEN LEGACY SOFTWARE AND SCREEN READER PROGRAMS” lapsed as from 11 March 2012, due to non-payment of the third renewal, due with extension period by 11 September 2012. IBM’s attorneys did not provide a sufficiently detailed affidavit explaining the reason for the patent lapsing and were given an opportunity to rectify this. It turns out that the renewal company they use gave insufficient information to their local agents who handle the renewals in Israel. This was considered adequate to allow a  notice of reinstatement to publish.

The relevant law is sections 57 and 60 of the Israel Patent Law.


Israel Patent Office Adopts New standards of obviousness for pharmaceutical patents

May 3, 2013

Morris Dancers and MaypoleCialis

IL 147642 to ICOS Corp. is a patent application for a treatment of erectile dysfunction that is marketed under the trade-name Cialis®. The treatment is based on the pharmaceutical active ingredient Tadalafil, where the distinguishing feature of the claimed invention concerns the size distribution of the particles of active ingredient.  A size distribution where 90% of particles are less than 40 micron diameter is claimed, with a preferred distribution being 90% of particles having a diameter between 10 micron and 25 micron.

In a decision of 24 October 2012, the Deputy Commissioner, Ms Yaara Shoshani Caspi, upheld an examiner’s decision to reject the application. The applicant, represented by Reinhold Cohen, filed a request for an oral hearing, the date of which was set for 1 May 2013.

In preparation for the hearing, ICOS submitted a reasoned statement showing the difference between the claimed invention and the prior art. On reading the decision, Ms Shoshani Caspi was persuaded that the claimed invention was not described in any of the citations and was therefore novel and fulfilled the requirements of Section 4 of the Israel Patent Law. Furthermore, although reducing the size of the active ingredient clearly increased the surface area thereof, aiding and facilitating dissolving and uptake of a fairly insoluble material, and increasing its effect, Ms Bracha considered that the priority date there were other techniques that might be considered, such as wetting the active ingredient.  She ruled that decreasing the particle size was not the only candidate for a technique that would be tried first, suggesting that persons of the art might try co-precipitation, for example. Indeed, there were various known disadvantages with decreasing the particle size, that although would not rule out this approach a priori, would, nevertheless, make it a less favorable choice.

Applicants argued that although β-carboline was made more instantly available by shrinking the particle size, persons of the art might not make the required analogy. Ms Shoshani Caspi found applicants arguments convincing and allowed the application to continue to publication rendering the hearing moot.

COMMENTS

In a recent attempted appeal to the Israel Supreme Court concerning  Merck’s treatment Fosamax®, Judge Handel of the Israel Supreme Court upheld the District Court and former Commissioner  of Patents, Dr Meir Noam’s ruling that the standard for rejecting a pharmaceutical invention as having inventive step or non-obviousness, is ‘obvious to try’.  Ms Bracha is specifically ruling that obvious to try is not enough to render a pharmaceutical patent to be considered non-inventive, demanding a higher standard – that of ‘obvious to try first‘ or ‘obvious to succeed’.

Since Handel rejected the request for an appeal, I am not sure that his ruling can be considered a binding precedent of the Israel Supreme Court. Nevertheless, it is clear that Ms Shoshani Caspi is adopting a more lenient standard than that required by Dr Noam. Time will tell if this indicates a change in policy by the Israel Patent Office. What seems most likely is that Unipharm and / or Teva will challenge the validity of this patent at least on the grounds of it being based on an invention that was obvious to try so at some stage, we will receive more clear guidance as to whether this is sufficient to render a claimed invention obvious.

I understand that May Day as the choice of date for the hearing has nothing to do with the impotence of International Workers or with Maypoles being a clear example of a phallic symbol.  The rather English image of Morris Dancers around a Maypole has nothing to do with the rather English Israel Patent Attorney, Michael Morris,  - a licensed practitioner that I trained some years ago. Indeed, I have no idea if he knows Morris Dancing.


Patents and the Global Health Crisis

April 29, 2013

Professor William Fisher tel aviv university

Professor William Fisher of Harvard Law School is giving the Sixth Annual Cegla Lecture on Legal Theory, entitled “Infection: The Health Crisis in the Developing World and What We Should Do About It“. The lecture will take place on Thursday, May 2, 2013 between 6 PM and 8 PM (18:00 and 20:00 for those that prefer the 24 hour convention).

The event will take pace in Tel Aviv University, the Buchmann Faculty of Law, Trubowitz Building, Somia Kossoy Conference Room, Room 207 on the third floor.

COMMENTS

Professor Michael Birnhack who is chairing the event refers to Professor William Fisher as Terry Fisher. He also claims that the lecture will deal with patents and the global health crisis.  The title and identity of the speaker therefore seem to be somewhat misleading!

That said, I have no doubt that Professors at Harvard Law School who get flown in to give an annual lecture are well worth listening to. I therefore hope that my readers on both sides of the patented medicine – generic debate (which, form feedback I receive seems to include many of the industrialists, patent attorneys and litigators) will come along to listen – and will behave themselves, i.e. polite heckling only, no rotten fruit.

 


US Court Fines Pearl Cohen Zedek Latzer LLP (PCZL) and its litigators $200,054 for filing and prosecuting a frivolous patent infringement law suit

April 26, 2013

shluker

Source Vagabond and Hydrapak are both companies that make hydration packs. These are what are known in Israel as ‘shlukers’ – flexible water bladders with shoulder straps that may be carried on the back by hikers.

Source Vagabond is an Israeli company that has several patents in the United States. One of these patents is US 7,648,276 is titled “Sealing device for flexible liquid container”.

In August 2011, Source Vagabond, represented by Pearl Cohen-Zedek Latzer (PCZL) sued Hydrapak for patent infringement, contending that the top closure system used in Hydrapak’s Reversible Reservoir II infringed upon Source Vagabond’s patent.

Even before the suit was dismissed last April, Hydrapak was awarded its own patents: US 8,043,005 and US 8,186,881 both titled “Reservoir Closure System And Method” for their novel closure method – which is a fair indication that their system is patently distinct from Source Vagabond’s and inventive thereover.

In April 2012, Hydrapak, represented by Morrison & Foerster’s patent litigation team, won a summary judgment of non-infringement for in the New York Federal Court. Not only was the case was thrown out, but the defendants won Rule 11 sanctions against the prosecuting counsel. Later that year, Source Vagabond appealed the ruling of non-infringement to the Court of Appeals for the Federal Circuit (the CAFC), where, following oral arguments, the court affirmed the District Court’s decision of non-infringement.

Following the appeal, Source Vagabond then filed for a motion for reconsideration:

Judge Colleen McMahon wrote in her decision:

Plaintiff’s proposed construction violates nearly every tenet of claim construction and amounts to a wholesale judicial rewriting of the claim.” In granting the award of sanctions, Judge McMahon noted that while “I and so many of my colleagues bridle at the flood of Rule 11 motions that arrive on our doorsteps,” in this case sanctions were warranted because “this case is simply not close on the merits.”

On February 21, 2013, Judge Colleen McMahon ruled that the law suit brought by Pearl Cohen Zedek Latzer on behalf of Vagabond was wholly without merit and ordered PCZL to pay $200,054 in costs to Hydrapak and their lawyers.

The decision was given following a motion for reconsideration, and that motion was itself considered frivolous. The court concluded that this case was not close on the merits and lacked any arguable basis in fact. That is the standard for imposing sanctions. Nothing in the papers filed in support of plaintiff’s motion for reconsideration cast the slightest doubt on that conclusion.

A particularly strong paragraph was the following:

In particular, nothing said by Judge Bryson (the Court of Appeal, Federal Circuit CAFC judge that heard the appeal MF), during oral argument on appeal even remotely suggests that he disagreed with this court’s conclusion that Source’s claim construction violated every relevant rule of claim construction. Hydrapak’s counsel’s statement during oral argument that it violated “every precedent” of both the Federal Circuit and the United States Supreme Court was obvious hyperbole, but the fact is that Judge Bryson, like every other judge who looked at this case on the merits, rejected Source’s claim construction and endorsed this court’s conclusions. Source is grasping at non-existent straws here. (parenthesis added)

What this means is that the arguments proposed by PCZL as being the meaning and scope of the claims being asserted were rejected completely. Hydrapak simply was not infringing Source Vagabond’s claims.

Accordingly, for the reasons set forth in Magistrate Judge Cott’s Report, the court awards sanctions of $187,308.65, plus an additional $12,745.35 in sanctions incurred in connection with the motion for reconsideration, for a total award of $200,054. The sanctions are imposed jointly and severally against Pearl Cohen Zedek Latzer LLP and the prosecuting attorneys Guy Yonay and Clyde Shuman.

The Case:  Source Vagabond Systems v. Hydrapak, 11 Civ. 5379 (SDNY, Decided February 21, 2013) ruling by Judge Colleen McMahon, Decided: February 21, 2013

The decision is found here. There is a fuller review of the case on Law.com – see here 

COMMENTS

This case raises a significant number of legal and ethical issues – enough for a series of articles.  In this first article we will look at the decision of sanctions on the complainant’s counsel.  Does PCZL and its lawyers have to pay the fine themselves, or can they roll these costs onto their client?

It would appear that under New York State law, all arguments and counter-arguments must be made at the submission of initial trial briefs.  Failure to timely object to a magistrate’s report and recommendation operates as a waiver of further judicial review of that decision. Consequently, Since PCZL did not challenge the contention that PCZL, Guy and Clyde are (jointly and separately) the only liable parties, and since they failed to argue that some of the culpability lies with their client Source Vagabond, the district court did not address the issue. Accordingly, should PCZL try to further appeal the court’s decision, we presume that it can only do so on the issue of the sum and the culpability and not on the issue of whether the “blame” and therefore the sanction should have been assessed against the client as well.

We can’t tell whether Source Vagabond pressed Pearl Cohen Zedek Latzer to file the case. We can’t tell if Source Vagabond asked PCZL for a legal opinion as to whether to file the initial complaint or the later filed motion for reconsideration. Indeed, we can’t tell if PCZL encouraged their client to sue, or even originated the idea. Such information is privileged between the attorney and client. It wouldn’t even have come out in discovery were this case to have been considered meritorious enough to continue to trial.  Because of this, we can only hypothesize regarding the background to PCZL’s decision in file a case considered by the judge as one that lacked any arguable basis in fact. However, since PCZL did not contest the culpability issue, the issue appears to be moot. Effectively they have assumed, if not admitted, sole responsibility. This could have ramifications if the client files a malpractice suit.

That as may be, it would appear that Source Vagabond got off lightly here, as the costs involved in fighting a case through the US courts can run into millions of dollars. Morrison & Foerster is a leading US law firm and their services no doubt don’t come cheap. Discovery laws make suing in the US a very expensive business, and one that is extremely time-consuming. Thus if the case had dragged on and been lost at a later stage – which seems likely as ‘every judge who has looked at the case on the merits, rejected Source’s claim construction’,  it would presumably have resulted in Source Vagabond having to pay very much larger expenses.


Adding Additional Material During Patent Oppositions in Israel

February 22, 2013

oppositionsIn Israel, after allowance a patent publishes for a three-month period for opposition purposes. If no opposition is filed, the patent is granted and a certificate issues.
the opposition allows third parties to submit evidence and arguments that the Examiner may have missed. Until a patent is finally granted, it cannot be enforced. there is thus a danger that opposers may change the nature of the opposition and keep supplying additional references of more or less relevance as a delaying tactic, to prevent the patent from issuing. To prevent such an occurrence, the regulations provides guidelines and deadlines for opposition procedures, and once evidence has been submitted, submitting further evidence is frowned upon. On the other hand, not allowing a killer reference to be submitted may result in an invalid patent issuing, which is also unacceptable, as this would result in the patentee being able to enforce rights he shouldn’t have.

Once a patent is granted, there is a presumption of validity. It is still possible to overcome this in the courts if the patentee sues for infringement and it is also possible for interested parties to initiate a voiding action.

IL 177724 and IL 205606 are a pair of patent applications filed by DSM IP Assets relating to reducing aggregation of cells in cell cultures. Refine Technologies LLC opposed these patent applications after they were allowed and published for publication purposes.

After filing their evidence, Refine Technologies wishes to add a further citation – US 5,871,999, arguing that the applicants had not yet responded and so doing so could not be considered a delaying tactic. They noted that a related PCT application was known to applicants, so there was little additional burden placed on them having to learn the new material. They explained that the new citation which was cited in a corresponding opposition process going on in Australia, indicated the scope and correct interpretation of the independent claim which they alleged was unclear.

DSM IP Assets opposed adding new the new material, arguing that it did not relate to issues of novelty or inventive step which were the grounds of opposition, and arguing that the request to add the material was a delaying tactic and was inequitable behaviour.

Deputy Commissioner Jaqueline Bracha dismissed arguments submitted that the request to add the material should be considered inequitable behaviour and ruled that the citation could be added at this stage. She went on to award interim costs of NIS 10,000 against the opposer.

COMMENT

The decision seems fair, but the award of costs appears to be a little steep.


Gilead and Teva Reach Agreement Regarding HIV Patent Validity Suit, Avoiding trial

February 20, 2013

viread

Teva Pharmaceuticals and Gilead Sciences Inc. agreed to settle a patent dispute over Viread, a treatment for HIV infection and chronic Hepatitis B, avoiding a trial that was scheduled to start today. Teva will be permitted to begin sales of a generic version of Viread on Dec. 15, 2017.  “We believe strongly in the validity of our intellectual property,” John Milligan, Gilead’s president, said in the statement yesterday. “This settlement, however, removes some uncertainty and minimizes further distraction.”

Gilead, based in Foster City, California, sued Teva in 2008 and again in 2010, claiming that Teva’s applications to the U.S. Food and Drug Administration to make drugs to treat HIV infections in adults infringed four of its patents. Teva, based in Petach Tikva, Israel, had said in court papers that Gilead’s patents were invalid and therefore couldn’t be infringed.

The trial in New York has been adjourned until the completion of the settlement agreement.

The case: Gilead Sciences v. Teva Pharmaceuticals USA, 10-01796, U.S. District Court, Southern District of New York (Manhattan).


Israel Patent Office Holds Training Seminar

February 19, 2013

patent office logo

Following the large number of changes relating to patent prosecution in Israel, the Israel Patent Authority held a seminar today, 19 February 2013.

There were three presentations. The first one, by the Chief Examiner, reviewed the duty of disclosure requirements and the various fees for filing and prosecuting patents.

The patent office stressed that the reduced filing fee of NIS 1200 (about what the fee used to be before the massive price hike at the beginning of the year), is ONLY for priority applications filed in Israel. All applicants, including individuals and companies that have small turnovers have to pay the full fee of NIS 2000 when filing a Paris Convention filing or a PCT national phase entry.  If the reduced fee is inadvertently paid for a Paris Convention filing, one receives the date of filing, but has to pay to the additional fee. With a PCT national phase entry, one does not receive a filing date until the correct fee has been paid. The reason for the difference was not explained. In the ensuing discussion, it was suggested to rearrange the list of fees to make it clear that the reduced payment and additional payment is only for first filings. In a second lecture, the person responsible for the new improved website explained a little about how to navigate. Various members of the audience pointed out flaws with the interface.  In a final lecture, the mystery of online PCT filings via uploading to the Israel Patent Office as receiving office via the website was elucidated.

The air-conditioning wasn’t working and it got a bit stuffy. The refreshments were a little frugal. About 65 people were present, but I am not sure how many were patent office staff and how many were practitioners – from the familiar faces, both were certainly present. As always, the seminar was a good opportunity to catch up with former employers, colleagues and employees.

The seminar was certainly helpful and timely.  I didn’t stay for the final lecture as I have recently managed to sort out direct PCT filings and have managed two filings over the past couple of weeks. If I hadn’t, I would certainly have stayed for that as well.

 

One interesting piece of news, though expected as a natural progression, was an informal announcement that the patent office was working towards online filing and prosecution via the website.  This should come in by the end of this year or next. We see this as a positive development, in that it should be more ecological in saving paper and petrol. We hope that eventually we will be able to look up actions on an official patent office docket using a customer service number, such as one’s license number.

I have expressed reservations regarding the patent office hosting European examiners and holding seminars on things like patentable subject matter, since examiners and practitioners are on different sides of the fence. Seminars regarding procedural matters are, however, certainly worthwhile events for the patent office to hold.

It was also nice seeing that the Israel Patent Office was investing in smoother procedures, an improved website etc., and not only charging more for their services.


Follow

Get every new post delivered to your Inbox.

Join 191 other followers